Funding opportunity: Cancer immunotherapy response research platform

  • Opportunity status: Upcoming
  • Funders: Medical Research Council (MRC)
  • Co-funders: Office of Life Sciences
  • Funding type: Grant
  • Total fund: £9,000,000
  • Maximum award: £9,000,000
  • Publication date: 11 October 2023
  • Opening date: To be confirmed
  • Closing date: Open - no closing date

Apply for funding to develop a broad utility, deep genotyping and phenotyping platform capable of generating insights into patient response, adverse effects, and resistance to immunotherapy, and exemplar project(s) to demonstrate utility.

The platform will be led by a multi-institutional and multi-disciplinary consortium, including at least one industry partner.

A total of £9 million (80% Full Economic cost (FEC) including relevant indexing) over 4 years is available with £4 million in FY 2024/25.

You must be a researcher employed at a research organisation eligible to apply for MRC funding.

This is a pre-announcement and the information may change.

The funding opportunity will open in January 2024. More information will be available on this page then.